Relacorilant ( DrugBank: Relacorilant )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 75 | クッシング病 | 18 |
75. クッシング病
臨床試験数 : 205 / 薬物数 : 176 - (DrugBank : 45) / 標的遺伝子数 : 61 - 標的パスウェイ数 : 127
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05347979 (ClinicalTrials.gov) | May 25, 2022 | 18/4/2022 | Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants | An Open-Label, Drug-Drug Interaction Study Designed to Evaluate the Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Subjects | Cushing Syndrome;Neoplasms | Drug: Dabigatran Etexilate;Drug: Relacorilant | Corcept Therapeutics | NULL | Completed | 18 Years | 55 Years | All | 30 | Phase 1 | United States |
| 2 | EUCTR2018-001616-30-NL (EUCTR) | 14/04/2022 | 12/10/2021 | Extension of a clinical trial to assess the safety of a study drug called CORT125134 in the treatment of Cushing Syndrome | An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome - CORT125134-452 | Endogenous Cushing Syndrome MedDRA version: 24.0;Level: LLT;Classification code 10011657;Term: Cushings syndrome;System Organ Class: 100000004860;Therapeutic area: Body processes [G] - Physiological processes [G07] | Product Code: CORT125134 INN or Proposed INN: Relacorilant Other descriptive name: (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | Corcept Therapeutics Incorporated | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 75 | Phase 2;Phase 3 | United States;Hungary;Canada;Spain;Poland;Romania;Austria;Bulgaria;Israel;Germany;Netherlands;Italy | ||
| 3 | EUCTR2018-001616-30-RO (EUCTR) | 29/12/2021 | 28/04/2022 | Extension of a clinical trial to assess the safety of a study drug called CORT125134 in the treatment of Cushing Syndrome | An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome | Endogenous Cushing Syndrome MedDRA version: 24.0;Level: LLT;Classification code 10011657;Term: Cushings syndrome;System Organ Class: 100000004860;Therapeutic area: Body processes [G] - Physiological processes [G07] | Product Code: CORT125134 INN or Proposed INN: Relacorilant Other descriptive name: (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | Corcept Therapeutics Incorporated | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 75 | Phase 2;Phase 3 | United States;Hungary;Canada;Spain;Poland;Romania;Austria;Bulgaria;Israel;Netherlands;Germany;Italy | ||
| 4 | EUCTR2018-001616-30-DE (EUCTR) | 22/12/2020 | 16/03/2020 | Extension of a clinical trial to assess the safety of a study drug called CORT125134 in the treatment of Cushing Syndrome | An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome | Endogenous Cushing Syndrome MedDRA version: 24.0;Level: LLT;Classification code 10011657;Term: Cushings syndrome;System Organ Class: 100000004860;Therapeutic area: Body processes [G] - Physiological processes [G07] | Product Code: CORT125134 INN or Proposed INN: Relacorilant Other descriptive name: (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | Corcept Therapeutics Incorporated | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 75 | Phase 2;Phase 3 | United States;Hungary;Canada;Spain;Poland;Romania;Austria;Bulgaria;Israel;Netherlands;Germany;Italy | ||
| 5 | EUCTR2018-001616-30-BG (EUCTR) | 27/03/2020 | 24/02/2020 | Extension of a clinical trial to assess the safety of a study drug called CORT125134 in the treatment of Cushing Syndrome | An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome | Endogenous Cushing Syndrome MedDRA version: 24.0;Level: LLT;Classification code 10011657;Term: Cushings syndrome;System Organ Class: 100000004860;Therapeutic area: Body processes [G] - Physiological processes [G07] | Product Code: CORT125134 INN or Proposed INN: Relacorilant Other descriptive name: (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | Corcept Therapeutics Incorporated | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 75 | Phase 2;Phase 3 | United States;Hungary;Canada;Spain;Poland;Romania;Austria;Israel;Bulgaria;Netherlands;Germany;Italy | ||
| 6 | EUCTR2018-001616-30-ES (EUCTR) | 14/02/2020 | 10/01/2020 | Extension of a clinical trial to assess the safety of a study drug called CORT125134 in the treatment of Cushing Syndrome | An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome | Endogenous Cushing Syndrome MedDRA version: 20.0;Level: LLT;Classification code 10011657;Term: Cushings syndrome;System Organ Class: 100000004860;Therapeutic area: Body processes [G] - Physiological processes [G07] | Product Code: CORT125134 INN or Proposed INN: Relacorilant Other descriptive name: (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | Corcept Therapeutics Incorporated | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 75 | Phase 2;Phase 3 | Canada;Austria;Netherlands;Romania;Hungary;United States;Poland;Italy;Israel;Bulgaria;Germany;Spain | ||
| 7 | EUCTR2018-003096-35-PL (EUCTR) | 05/07/2019 | 12/04/2019 | A study to assess whether a product called relacorilant works and is safe to use in patients with Cushing Syndrome; some patients will receive relacorilant whilst others receive a placebo. | Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant - GRACE | Endogenous Cushing syndrome MedDRA version: 24.0;Level: LLT;Classification code 10011657;Term: Cushings syndrome;System Organ Class: 100000004860;Therapeutic area: Body processes [G] - Physiological processes [G07] | Product Name: Relacorilant Product Code: CORT125134 INN or Proposed INN: Relacorilant Other descriptive name: (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4YL)SULFONYL)4,4A,5,6,7,8HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN4AYL)(4(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | Corcept Therapeutics Incorporated | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 145 | Phase 3 | Canada;Austria;Netherlands;Romania;United States;Poland;Italy;Israel;Bulgaria;Germany;Spain | ||
| 8 | EUCTR2018-003096-35-NL (EUCTR) | 19/06/2019 | 11/12/2018 | A study to assess whether a product called relacorilant works and is safe to use in patients with Cushing Syndrome; some patients will receive relacorilant whilst others receive a placebo. | Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant - CORT125134-455 | Endogenous Cushing syndrome MedDRA version: 20.0;Level: LLT;Classification code 10011657;Term: Cushings syndrome;System Organ Class: 100000004860;Therapeutic area: Body processes [G] - Physiological processes [G07] | Product Name: Relacorilant Product Code: CORT125134 INN or Proposed INN: Relacorilant Other descriptive name: (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | Corcept Therapeutics Incorporated | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 130 | Phase 3 | United States;Canada;Spain;Poland;Romania;Austria;Bulgaria;Israel;Germany;Netherlands;Italy | ||
| 9 | EUCTR2018-003096-35-BG (EUCTR) | 05/06/2019 | 28/01/2019 | A study to assess whether a product called relacorilant works and is safe to use in patients with Cushing Syndrome; some patients will receive relacorilant whilst others receive a placebo. | Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant - GRACE | Endogenous Cushing syndrome MedDRA version: 20.0;Level: LLT;Classification code 10011657;Term: Cushings syndrome;System Organ Class: 100000004860;Therapeutic area: Body processes [G] - Physiological processes [G07] | Product Name: Relacorilant Product Code: CORT125134 INN or Proposed INN: Relacorilant Other descriptive name: (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | Corcept Therapeutics Incorporated | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 145 | Phase 3 | United States;Canada;Spain;Poland;Romania;Austria;Israel;Bulgaria;Netherlands;Germany;Italy | ||
| 10 | EUCTR2018-003096-35-AT (EUCTR) | 31/05/2019 | 15/02/2019 | A study to assess whether a product called relacorilant works and is safe to use in patients with Cushing Syndrome; some patients will receive relacorilant whilst others receive a placebo. | Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant - GRACE | Endogenous Cushing syndrome MedDRA version: 20.0;Level: LLT;Classification code 10011657;Term: Cushings syndrome;System Organ Class: 100000004860;Therapeutic area: Body processes [G] - Physiological processes [G07] | Product Name: Relacorilant Product Code: CORT125134 INN or Proposed INN: Relacorilant Other descriptive name: (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | Corcept Therapeutics Incorporated | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 145 | Phase 3 | United States;Canada;Spain;Poland;Romania;Austria;Bulgaria;Israel;Netherlands;Germany;Italy | ||
| 11 | EUCTR2018-003096-35-ES (EUCTR) | 23/05/2019 | 12/04/2019 | A study to assess whether a product call relacorilant works and is safe to use in patients with Cushing Syndrome; some patients will receive relacorilant whilst others receive a placebo. | Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant - GRACE | Endogenous Cushing syndrome MedDRA version: 20.0;Level: LLT;Classification code 10011657;Term: Cushings syndrome;System Organ Class: 100000004860 ;Therapeutic area: Body processes [G] - Physiological processes [G07] | Product Name: Relacorilant Product Code: CORT125134 INN or Proposed INN: Relacorilant Other descriptive name: (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | Corcept Therapeutics Incorporated | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 130 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no | United States;Canada;Poland;Spain;Austria;Israel;Bulgaria;Netherlands;Germany;Italy | ||
| 12 | EUCTR2018-003096-35-IT (EUCTR) | 21/02/2019 | 27/01/2021 | A study to assess whether a product called relacorilant works and is safe to use in patients with Cushing Syndrome; some patients will receive relacorilant whilst others receive a placebo. | Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant - GRACE | Endogenous Cushing syndrome MedDRA version: 20.0;Level: LLT;Classification code 10011657;Term: Cushings syndrome;System Organ Class: 100000004860;Therapeutic area: Body processes [G] - Physiological processes [G07] | Product Name: Relacorilant Product Code: [CORT125134] INN or Proposed INN: Relacorilant Other descriptive name: (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4- | CORCEPT THERAPEUTICS | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 145 | Phase 3 | United States;Canada;Spain;Poland;Romania;Austria;Bulgaria;Israel;Netherlands;Germany;Italy | ||
| 13 | NCT03697109 (ClinicalTrials.gov) | October 16, 2018 | 27/9/2018 | A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome | Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant | Cushing Syndrome | Drug: Relacorilant;Other: Placebo | Corcept Therapeutics | NULL | Recruiting | 18 Years | 80 Years | All | 130 | Phase 3 | United States;Austria;Bulgaria;Canada;Germany;Israel;Italy;Netherlands;Poland;Romania;Spain |
| 14 | EUCTR2018-001616-30-IT (EUCTR) | 19/07/2018 | 29/01/2021 | Extension of a clinical trial to assess the safety of a study drug called CORT125134 in the treatment of Cushing Syndrome | An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome - - | Endogenous Cushing Syndrome MedDRA version: 20.0;Level: LLT;Classification code 10011657;Term: Cushings syndrome;System Organ Class: 100000004860;Therapeutic area: Body processes [G] - Physiological processes [G07] | Trade Name: NA Product Name: NA Product Code: [CORT125134] INN or Proposed INN: Relacorilant | CORCEPT THERAPEUTICS | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 75 | Phase 2 | United States;Hungary;Spain;Bulgaria;Germany;Italy | ||
| 15 | EUCTR2018-001616-30-HU (EUCTR) | 09/07/2018 | 14/05/2018 | Extension of a clinical trial to assess the safety of a study drug called CORT125134 in the treatment of Cushing Syndrome | An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome | Endogenous Cushing Syndrome MedDRA version: 20.0;Level: LLT;Classification code 10011657;Term: Cushings syndrome;System Organ Class: 100000004860;Therapeutic area: Body processes [G] - Physiological processes [G07] | Product Code: CORT125134 INN or Proposed INN: Relacorilant Other descriptive name: (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | Corcept Therapeutics Incorporated | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 75 | Phase 2 | United States;Hungary;Italy | ||
| 16 | NCT03604198 (ClinicalTrials.gov) | May 7, 2018 | 1/5/2018 | Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome | An Open-Label Extension Study of the Safety of Relacorilant in the Treatment of the Signs and Symptoms of Cushing Syndrome | Cushing Syndrome | Drug: relacorilant | Corcept Therapeutics | NULL | Enrolling by invitation | N/A | N/A | All | 75 | Phase 2 | United States;Austria;Bulgaria;Germany;Israel;Italy;Netherlands;Poland;Romania;Spain |
| 17 | EUCTR2016-000899-23-GB (EUCTR) | 16/08/2016 | 21/06/2016 | Clinical trial to assess the safety and effectiveness of a study drug called CORT125134 in the treatment of Cushing's syndrome | Phase 2 Study of the Safety and Efficacy of CORT125134 in the Treatment of Endogenous Cushing’s Syndrome | Endogenous Cushing’s Syndrome MedDRA version: 20.0;Level: LLT;Classification code 10011657;Term: Cushings syndrome;System Organ Class: 100000004860 ;Therapeutic area: Body processes [G] - Physiological processes [G07] | Product Code: CORT125134 INN or Proposed INN: Relacorilant | Corcept Therapeutics Incorporated | NULL | Not Recruiting | Female: yes Male: yes | 30 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | United States;Hungary;Netherlands;United Kingdom | ||
| 18 | EUCTR2018-003096-35-DE (EUCTR) | 14/06/2019 | A study to assess whether a product called relacorilant works and is safe to use in patients with Cushing Syndrome; some patients will receive relacorilant whilst others receive a placebo. | Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant - GRACE | Endogenous Cushing syndrome MedDRA version: 20.0;Level: LLT;Classification code 10011657;Term: Cushings syndrome;System Organ Class: 100000004860;Therapeutic area: Body processes [G] - Physiological processes [G07] | Product Name: Relacorilant Product Code: CORT125134 INN or Proposed INN: Relacorilant Other descriptive name: (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | Corcept Therapeutics Incorporated | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 145 | Phase 3 | Canada;Austria;Netherlands;Romania;United States;Poland;Italy;Israel;Bulgaria;Germany;Spain |